WAS have yielded thousands of robustly associated variants for schizophrenia and many other complex traits, but relatively few of these associations have implicated specific biological mechanisms 1, 2 , because GWAS signals often span many putative target genes, may affect gene expression through regulatory 3 or structural elements 4 , and may affect genes at considerable genomic distances via chromatin looping 5, 6 . A growing body of research has demonstrated the enrichment of schizophrenia GWAS risk variants and heritability within regulatory elements, as identified through maps of chromatin modifications and accessibility 1, [7] [8] [9] [10] [11] [12] [13] . Because chromatin modifications are themselves under genetic control 6, [14] [15] [16] [17] [18] [19] , a plausible causal mechanism for most schizophrenia loci is genetic variation leading to regulatory changes marked by chromatin, to gene expression, and finally to disease risk. Indeed, quantitative trait loci (QTLs) for chromatin (and other molecular phenotypes) are enriched within GWAS associations, thus further supporting this hypothesis 6, 18, 20, 21 . In this work, we leveraged gene-expression and splicing data from schizophrenia and bipolar cases and controls in the brain, as well as gene-expression data from controls in other tissues, to perform a TWAS [22] [23] [24] in a large schizophrenia GWAS dataset 1 and to identify genes whose expression is genetically correlated with schizophrenia. We subsequently performed a TWAS for a diverse set of chromatin phenotypes to connect putative schizophrenia-susceptibility genes with specific regulatory elements. To our knowledge, this is the first TWAS for any disease to integrate analysis of gene expression, splicing, and chromatin variation, and it has moved beyond top SNPs to implicate schizophrenia-associated molecular phenotypes across the regulatory cascade (Fig. 1) . 
, because GWAS signals often span many putative target genes, may affect gene expression through regulatory 3 or structural elements 4 , and may affect genes at considerable genomic distances via chromatin looping 5, 6 . A growing body of research has demonstrated the enrichment of schizophrenia GWAS risk variants and heritability within regulatory elements, as identified through maps of chromatin modifications and accessibility 1, [7] [8] [9] [10] [11] [12] [13] . Because chromatin modifications are themselves under genetic control 6, [14] [15] [16] [17] [18] [19] , a plausible causal mechanism for most schizophrenia loci is genetic variation leading to regulatory changes marked by chromatin, to gene expression, and finally to disease risk. Indeed, quantitative trait loci (QTLs) for chromatin (and other molecular phenotypes) are enriched within GWAS associations, thus further supporting this hypothesis 6, 18, 20, 21 . In this work, we leveraged gene-expression and splicing data from schizophrenia and bipolar cases and controls in the brain, as well as gene-expression data from controls in other tissues, to perform a TWAS [22] [23] [24] in a large schizophrenia GWAS dataset 1 and to identify genes whose expression is genetically correlated with schizophrenia. We subsequently performed a TWAS for a diverse set of chromatin phenotypes to connect putative schizophrenia-susceptibility genes with specific regulatory elements. To our knowledge, this is the first TWAS for any disease to integrate analysis of gene expression, splicing, and chromatin variation, and it has moved beyond top SNPs to implicate schizophrenia-associated molecular phenotypes across the regulatory cascade ( Fig. 1) .
, expression array data measured in blood from 1,264 control individuals from the Young Finns Study (YFS) 23 , and RNA-seq data measured in adipose tissue from 563 control individuals from the Metabolic Syndrome in Men study (METSIM) 23 ; pre-computed weights from ref. 23 were used for the YFS/METSIM studies. We further characterized splicing events 27 in the CMC brain RNA-seq data (Methods). The average cis and trans estimates of the SNP heritability of expression (h g 2 , Methods) were highly significant in each panel, with a total of a total of 18,084 genes summed across the four panels (10,819 unique genes; Supplementary Table 1) , as well as an additional 9,009 splicing events in the brain (in 3,908 unique genes; Supplementary Table 1) exhibiting nominally significant cis-h g 2 (P < 0.01 by likelihood ratio test).
We performed a TWAS using each of the four gene-expression reference panels and summary-level data from the Psychiatric Genomics Consortium (PGC) schizophrenia GWAS of 79,845 individuals 1 to identify genes associated with schizophrenia ( Fig. 1 and Supplementary Fig. 1a ). Briefly, this approach integrated information from expression reference panels (SNP-expression correlation), GWAS summary statistics (SNP-schizophrenia correlation), and linkage disequilibrium (LD) reference panels (SNP-SNP correlation) to assess the association between the cis-genetic component of expression and phenotype (expression-schizophrenia correlation) 23 . In practice, the expression reference panel was used as the LD reference panel, and cis-SNP-expression effect sizes were estimated with a sparse mixed linear model 28 (Methods) . Because schizophrenia is a highly polygenic trait, we expected these control reference samples to carry disease-affecting regulatory variants. By leveraging genetic predictors of expression, our approach was not affected by reverse causality (disease → expression), but pleiotropic effects on expression and trait could not be ruled out without additional analyses (Discussion) 23 . The TWAS identified 247 transcriptome-wide-significant geneschizophrenia and intron-schizophrenia associations (summed across expression reference panels) for a total of 157 unique genes, including 49 genes that were significant in more than one expression panel (Fig. 2 , Table 1, Supplementary Fig. 2 and Supplementary  Tables 2 and 3 ). We observed no significant differences when performing the TWAS by using brain expression data from schizophrenia/bipolar cases or controls separately, thus confirming that the presence of cases in the reference panel did not affect our results (Supplementary Note and Supplementary Table 4) . We observed hotspots 29 of multiple TWAS-associated genes at 33 loci (defined by genes < 500 kb apart). However, only 6/33 loci exhibited evidence of statistically independent genetic effects in a summary-based joint test 30 , thus suggesting that most of these loci could be explained by a single underlying genetic effect (Methods and Supplementary  Table 3 ). Across all TWAS associations, the implicated gene was the nearest gene to the top SNP at the locus in only 56% of instances (with the 10,819 cis-heritable genes used as background; this value decreased to 24% of instances when all 26,469 known RefSeq genes were used), thus underscoring previous findings 23, 24, 29, 31 . We confirmed that the summary-based approach was consistent with individual-level predictions by using individual-level PGC data, and we replicated the associations in aggregate by using out-of-sample schizophrenia plus bipolar phenotypes (Supplementary Note, Supplementary Tables 5  and 6 , and Supplementary Figs. 1a and 3-5 ).
Of the 108 published PGC GWAS regions 1 , 47 regions were located near (± 500 kb) at least one TWAS gene (accounting for 122/157 genes), and the remaining 35/157 genes implicated novel targets. The GWAS association statistics at novel TWAS loci were often well below genome-wide significance ( Supplementary Fig. 6 ), and we hypothesized that some of the new discoveries might be driven by the TWAS aggregating partially independent effects on schizophrenia that operate through a single gene. As evidence of this model, the TWAS association was stronger than the lead SNP for 27% of TWAS associations that did not overlap a genome-wide-significant SNP, but for only 3% of TWAS associations that did overlap a genomewide-significant SNP (Fisher's exact P = 8.1 × 10
−7
). Across all TWAS associations, 21/247 were more significant than the lead GWAS SNP, and the percentage of cis expression heritability that was explained by the top expression QTL (eQTL) for these 21 genes was significantly lower than that for the rest (56% versus 88%, t-test P = 9.6 × 10
), a result indicative of secondary QTL effects. We excluded the major (E g ) is learned in a reference panel (top), integrated with schizophrenia GWAS association statistics to infer schizophrenia-E g association (middle), and further integrated with individual-level chromatin phenotypes to infer genes with schizophrenia and chromatin-E g associations (bottom). Detailed analysis flowchart in Supplementary Fig. 1 . SCZ, schizophrenia.
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histocompatibility complex region (chromosome (chr) 6: 28-34 Mb) from our primary analyses because of its complex haplotype and LD structure. However, as a positive control, we specifically tested the C4A gene, which has recently been fine mapped for schizophrenia 4 and lies inside the major histocompatibility complex region, and we confirmed a highly significant TWAS association between C4A expression in brain tissue and schizophrenia (P = 1.8 × 10
−18
). Splicing events in the brain accounted for 46 transcriptomewide-significant gene associations (of which ten were at novel loci), a number comparable to the 44 significant gene associations from the brain (Table 1 and Supplementary Table 3) , although splicing events accounted for 30% fewer significantly cis-heritable genes than total expression (Supplementary Table 1 ). Overall, 20/46 associations corresponded to genes that were not tested in the analysis of total gene expression, owing to nonsignificant expression heritability, and 19 of the remaining 26 associations did not have a transcriptome-wide-significant association for total gene expression. This result was consistent with the recent observation that splicing Transcriptome-widesignificant associations are highlighted as red points, with jointly significant independent associations (Methods) labeled with gene names and color coded according to expression reference (red, CMC; blue, METSIM; purple, YFS; green, NTR; black, all). Bottom, polygenic TWAS effects across reference tissues. Out-of-sample schizophrenia prediction R 2 for GE-PRS as a function of significance cutoff. Significant correlations (after Bonferroni correction for number of thresholds tested) are indicated with an asterisk, and the most significant P value is reported. Rightmost panel shows prediction from all tissues jointly (black) and from CMC brain genes plus splicing events jointly (red). R 2 was computed after subtraction of ancestry principal components and conversion to liability scale with a population prevalence of 1%. QTLs are typically independent of eQTLs at the same gene 27 . We caution that effect direction for splicing events is difficult to interpret because alternatively spliced exons are often negatively correlated (Supplementary Note and Supplementary Fig. 7 ). Although the largest number of associations came from the brain, the enrichment was not striking after the total number of heritable genes was accounted for (Table 1) , thus suggesting that expression-data quality and sample size currently are more important than tissue specificity in finding significant associations.
TWAS associations may be caused by coincidental overlap between eQTLs and noncausal disease variants at a GWAS locus, a possibility that we investigated through formal colocalization and conditional analyses. First, we used the COLOC method 32 to estimate the posterior probability of a single shared causal variant for TWAS-implicated genes and schizophrenia by using the marginal association statistics. We calibrated a 5% false-discovery threshold for considering a gene 'colocalized' , using randomly selected heritable genes in the same schizophrenia GWAS regions (Methods). Colocalization between eQTLs and schizophrenia was observed for 55% of the TWAS-implicated genes ( Supplementary Fig. 8 and Supplementary Table 3 ). We note that COLOC's posterior is highly dependent on the prior probability of a single shared causal variant ( Supplementary Fig. 9 ) and is conservative when multiple causal variants mediate the effects on expression and trait 23 , so that colocalization at the remaining loci may be underestimated. For the 45% genes that did not significantly colocalize, the percentage of cis expression heritability explained by the top eQTL was lower than that explained by the rest (79% versus 89%), thus suggesting secondary effects; however, the difference was not statistically significant. Second, conditioning on the predicted expression of a TWAS-associated gene (using summary-level data 30 ; Methods) reduced the χ 2 of the lead GWAS SNP at the locus (including genome-wide-significant and nonsignificant loci) from 42 to 10 on average, and explained more of the association signal than did conditioning on the corresponding top eQTL (Supplementary Table 7 ). For the 43 lead GWAS SNPs at genome-wide-significant loci that were correlated (r 2 > 0.05) with the predicted expression of at least one TWAS-significant gene (out of 47 overlapping index SNPs), joint conditioning on the predicted expression of all such genes decreased the median SNP P value from P = 1.2 × 10 −10 to P = 0.028 (Methods and Supplementary Table 8 ). Given that the expression predictor typically captures only 60-80% of the cis component of gene expression at the expression-panel sample sizes used here 23 , the complete elucidation of the cis component may potentially explain the entire GWAS signal at these loci.
This schizophrenia GWAS dataset 1 has recently been evaluated in a TWAS with gene expression in blood through summary-based Mendelian randomization (SMR) 24 , which identified 16 transcriptome-wide-significant associated genes (in contrast to 157 identified here). Of the 16 gene associations identified by SMR, 12 were tested in our study in blood; all replicated at nominal P <0.05 (with consistent sign), and 9 were transcriptome-wide significant-a striking concordance given the different methods and independent expression panels used.
Functional validation of TWAS-associated genes by using chromatin-interaction data. We leveraged recently published chromatin-interaction (Hi-C) data in the developing human brain 33 to investigate whether TWAS-associated genes were supported by physical chromatin interactions that occur during brain Number of unique genes significantly associated with a chromatin peak after Bonferroni correction for a given distance from the gene (x axis), determined by using the top eSNP in the chromatin cohort (left) or using chromatin TWAS from all reference panels (right). Results from CEU and YRI populations are shown at top and bottom, respectively.
development ( Supplementary Fig. 1b) . We used the Hi-C data to construct a set of comparison schizophrenia-risk genes on the basis of 3D chromatin interactions between gene transcription start sites (TSSs) and SNPs in the fine-mapped 95%-causal credible set (Methods). This procedure yielded a set of 59 loci with both TWAS and fine-mapped Hi-C data, containing 474 Hi-C-predicted schizophrenia-risk genes. The 474 Hi-C-predicted genes overlapped with 105/157 TWAS-associated genes (Supplementary Fig. 10 ; Fisher's exact test P = 1.03 × 10
, odds ratio = 4.68 compared with random heritable genes at these loci), thus indicating that most of the TWASassociated genes were supported by 3D chromatin interactions with a schizophrenia SNP in the developing brain. The TWAS associations were also significantly correlated with higher expression during mid-fetal developmental in independent samples (P < 0.05/19; Supplementary Note and Supplementary Figs. 11 and 12 ), thus further underscoring the etiological relevance of mechanisms active during brain development.
Polygenic TWAS signal largely explained by expression in the brain. To assess the full polygenic architecture of the TWAS associations, we relaxed the transcriptome-wide-significance threshold and constructed gene-based polygenic risk scores (GE-PRS) from their predicted expression in the CMC (schizophrenia plus bipolar) case-control samples ( Supplementary Fig. 1c ). For each out-of-sample individual, the GE-PRS was the sum of predicted expression weighted by its signed schizophrenia TWAS Z score (Methods). The GE-PRS was significantly associated with schizophrenia status (conditioned on ancestry) across the full spectrum of TWAS association P values (Fig. 2) , as seen with SNP-based polygenic scores 1, 34, 35 . Although the prediction was significant in all tissues individually, there was clear evidence of an increased effect in the brain (in contrast to the transcriptome-wide-significant results), and the prediction from the brain (genes and splicing events) captured 92% of the joint prediction from all tissues ( Fig. 2 and Supplementary Fig. 13 ). A GE-PRS from actual measured expression and differential splicing in the brain was significant but substantially less so than the genetic GE-PRS ( Supplementary  Fig. 13 ). According to polygenic theory 36, 37 , the best TWAS GE-PRS was estimated to account for 26% of the total schizophrenia SNP heritability, thus providing an upper bound on the amount of trait variance that could be mediated by the steady-state expression in these tissues (Supplementary Note).
Chromatin TWAS identifies specific regulatory features associated with expression. We next sought to identify relationships between the expression of TWAS genes and cis regulatory elements marked by chromatin activity. We used population-level chromatin immunoprecipitation-DNA sequencing (ChIP-seq) chromatin phenotypes measured in 76 HapMap Yoruba in Ibadan, Nigeria (YRI) lymphoblastoid cell lines (LCLs) for acetylated histone H3 Lys27 (H3K27ac; marking active enhancers), methylated H3 Lys4 (H3K4me1; enhancers), trimethylated H3 Lys4 (H3K4me3; promoters), and DNase I-hypersensitive sites (DHS; open chromatin) 6 , and in 45 HapMap Utah residents with Northern and Western European ancestry from the CEPH collection (CEU) LCLs for H3K27ac, H3K4me1, H3K4me3, the regulatory transcription factor PU1, and RNA polymerase II (RPB2, associated with active transcription) 18 . For each of the nine chromatin phenotypes, regions with an excess of ChIP-seq reads were segmented into local peaks, and the chromatin abundance within each peak was treated as a quantitative trait 6, 18 . Both cohorts additionally had gene expression measured by RNA-seq in the same samples, and we confirmed that the genetic correlation was highly significant between expression and each chromatin mark (as well as between different chromatin marks) and persisted as far as 500 kb from the TSS ( Supplementary  Figs. 14-16, Supplementary Table 9 and Methods).
We applied individual-level TWAS methods 23 to predict expression of the 10,819 significantly heritable genes and 9,009 differentially spliced introns into samples with chromatin phenotypes and searched for expression-chromatin associations ( Fig. 1 and Supplementary Fig. 1d ). Prediction was performed from expression to chromatin-phenotype samples (instead of from chromatin-phenotype to expression samples) because of higher prediction accuracy in the larger expression panels, but this choice was agnostic to the direction of causality (Supplementary Note). Our approach yielded an average of 2.4× more Bonferroni-significant expression-chromatin associations than the conventional approach using in-sample lead cis expression-associated SNP (eSNP)-chromatin QTL (cQTL) overlap 38, 39 , primarily because of associations > 10 kb from the TSS (Fig. 3 and Supplementary Fig. 17 ). We obtained similar results when overlapping all cis eQTLs 6, 18 Table 10) . Across all tissues, 806 unique genes had a transcriptome-wide-significant association (Methods) with at least one chromatin phenotype ( Supplementary Fig. 18b and Supplementary Table 11 ), and 4,294 genes were significant at the 10% (per-phenotype) false discovery rate (FDR) used in previous studies 6, 18 (Supplementary Table 12 ). In contrast, only 224 of 9,009 splicing events in the CMC had a transcriptome-wide-significant chromatin association, corresponding to two-to three-times-fewer associations than we identified by using total CMC gene expression (depending on the chromatin phenotype; Supplementary Table 13) . Half of the chromatin associations were distal (10-500 kb from the TSS), and these were significantly enriched in Hi-C interactions in LCLs 6 relative to random (distance-matched) gene-peak pairs ( Supplementary Figs. 1g and 21-24) . No other differences in chromatin-mark usage or mark-gene distance were observed across the expression reference panels. However, we found that genes with associations with multiple chromatin peaks were more likely to be driven by a single eQTL (Supplementary Table 14) , thus suggesting that multiple chromatin TWAS peaks were typically related by a single genetic mechanism.
We used the measured RNA-seq expression in the chromatin individuals to confirm these associations. Across the 806 chromatin TWAS-associated genes, the correlation between measured expression and an associated chromatin phenotype was highly significant when compared against a distance-matched background null ( Supplementary Figs. 1e and 14b) , and the average TWASassociated chromatin peak explained a striking 20% of the variance in expression of its target gene in CEU (Supplementary Figs. 25-28 and Supplementary Table 16 ). For the three chromatin phenotypes that were measured in both CEU and YRI, chromatin TWAS peaks implicated in one population were predictive of a correlation with measured expression in the other (Supplementary Figs. 1f, 29 and 30, and Supplementary Table 17) , thus supporting our use of chromatin phenotypes from multiple populations.
Putative regulatory mechanisms for schizophrenia-associated genes. Focusing on the 157 transcriptome-wide-significant genes from the schizophrenia TWAS, we identified 42 genes (including seven genes at novel loci) that also had Bonferroni-significant chromatin TWAS associations (to a total of 78 individual chromatin peaks) in analyses using the same expression reference panel (Tables 1 and 2, Supplementary Fig. 1h and Supplementary  Tables 3, 18 and 19) . Only 8 of the 78 chromatin peaks underlying joint schizophrenia TWAS and chromatin TWAS associations were within the promoter (± 2 kb from the TSS) of their associated gene, thus suggesting that most regulatory elements affecting schizophrenia are distally located, as previously observed in other traits 6, 8, 20 . Schizophrenia TWAS genes were nominally enriched in chromatin TWAS associations (odds ratio = 1.53, Fisher's exact P = 4 × 10 −4
), but the effect was largely dampened after matching on the cisgenetic properties of genes (P = 0.01; Supplementary Table 20) and may potentially be explained by other unknown properties.
We observed significant evidence of chromatin-schizophrenia association and colocalization for most of the identified peaks by using independent statistical methods ( Supplementary Fig. 1h) . We analyzed the subset of schizophrenia TWAS loci with expressionchromatin associations by applying COLOC to (i) SNP-expression and SNP-chromatin association data to investigate expressionchromatin colocalization and (ii) SNP-chromatin and SNP-schizophrenia association data to investigate chromatin-schizophrenia colocalization. Colocalization was observed for 100% of the expression-chromatin associations and 97% of the chromatin-schizophrenia associations in CEU ( Supplementary Fig. 8 and Supplementary Table 19 ). The chromatin associations in YRI pose a model violation for COLOC, owing to differences in LD structure between populations, but colocalization still remained much higher than background, and 70% (43%) of expression-chromatin (chromatinschizophrenia) associations colocalized ( Supplementary Fig. 8 ).
Estimating pleiotropic associations between chromatin activity and schizophrenia by using SMR 24 (which tests only the best cQTL) or predicting chromatin activity by using a TWAS-like test (testing all SNPs in the Bayesian sparse linear mixed model (BSLMM) predictor) replicated > 60% of the associations at Bonferroni significance and > 90% at P < 0.05 (Supplementary Note and Supplementary  Tables 3, 19 and 21) . However, the chromatin sample size was insufficient to robustly estimate genetic predictors of chromatin and carry out a full chromatin-wide association study.
Examples of schizophrenia and chromatin TWAS loci. We highlight three examples of TWAS associations with both schizophrenia and chromatin phenotypes. We visualized these loci by using a 'TWAS scatter plot' of the relationship between each marginal GWAS-QTL association (Z score, y axis) and the correlation (x axis) between TWAS-predicted expression (GE pred ) and the marginal GWAS-QTL association. This relationship was expected to be linear and without outliers under the TWAS model (Figs. 4 and 5 , Supplementary Figs. 32-34 and Supplementary Note).
First, the total expression of PPP2R3C in NTR blood was associated with schizophrenia (TWAS P = 3.4 × 10
)-despite no genome-wide-significant SNPs at the locus-as well as four distal chromatin peaks (minimum P = 1.0 × 10 −9
; Fig. 4) . Conditioning each GWAS SNP on the predicted expression of PPP2R3C explained all significant marginal associations for the implicated phenotypes, and formal colocalization was supported between all features and schizophrenia (average posterior = 92%; Supplementary Table 24) . PPP2R3C was the nearest gene to the most significantly associated SNP at the locus and to the implicated chromatin peaks. However, because the locus was not genome-wide significant, this association would not have been identified in a conventional analysis of known GWAS loci. PPP2R3C has recently been identified by SMR analysis of schizophrenia in an independent expression panel 24 , and our findings pinpoint specific regulatory elements for experimental follow-up.
Second, a splicing event at KLC1 in CMC had a schizophrenia TWAS P = 6.7 × 10 −12 and overlapping H3K4me1/me3 chromatin 
CMC brain splicing
Novel, not overlapping with 108 PGC schizophrenia GWAS loci. b No significant schizophrenia colocalization posterior in any reference (excluding chromatin features in YRI). Forty-two genes (including the seven genes at novel loci a ) had a significant TWAS association with schizophrenia and chromatin phenotypes. For each significant TWAS association with schizophrenia, the number of significant genechromatin associations (family-wise error rate 5% among TWAS gene-mark associations, by Bonforroni correction) are reported. In the middle columns, dashes represent genes that were not heritable in the study and therefore not TWAS associated. In the right columns, dashes represent no identified association; genes with no chromatin associations are not shown. Top, results from genes, with TSS listed as position; bottom, results from splicing events in CMC with exon-exon junction listed as position (details in Supplementary Table 18 ). For loci without additional evidence of colocalization of cQTL/eQTL with schizophrenia b , full numerical results are shown in Supplementary Table 3 .
TWAS associations (minimum P = 2.5 × 10
) (Fig. 5) . Conditioning on the top splicing QTL explained all significant schizophrenia GWAS signal at the locus, whereas conditioning on the most significant eQTL had a negligible effect, thus highlighting an effect on schizophrenia that was explained by splicing and was independent of total expression. Notably, both chromatin TWAS associations were supported by Hi-C interactions with the KLC1 promoter in the developing brain 33 (FDR 0.01 significant, and the most significant interaction in the locus), thus providing a functional validation of coordinated activity ( Fig. 5 and Supplementary  Fig. 35 ). We performed a TWAS-like test for chromatin-schizophrenia association, which was highly significant for both peaks (best P = 2.6 × 10 −13 ; Supplementary Table 3) . Evidence for colocalization was high for KLC1 splicing and schizophrenia (posterior = 58%) as well as for the chromatin phenotypes and both KLC1 splicing and schizophrenia (posterior > 80%), even though the chromatin phenotypes were identified in YRI and may exhibit LD differences across populations (Supplementary Table 24 ). Differential DNA methylation 40 and expression at KLC1 in schizophrenia cases versus controls has recently been identified in two independent analyses of brain tissue, thus further supporting a cis-regulatory effect on schizophrenia.
Third, total expression of MAPK3 in CMC brain data was associated with schizophrenia (P = 1.3 × 10 ) and RPB2 (P = 1 × 10
−11
). In the CEU chromatin phenotype samples, in which MAPK3 expression was also measured in LCLs, the H3K27ac and RPB2 peaks explained 36% (P = 7 × 10 −6
) and 23% (P = 5 × 10 −4 ) of the variance in measured expression, respectively, but only the H3K27ac peak was significant in a joint model. Formal colocalization analysis supported a single shared causal variant across all eQTL-cQTL-GWAS combinations for the implicated features (posterior probabilities 54-97%; Supplementary Table 24) . We confirmed that the associated peaks were observed in epigenetic data from H3K27ac, H3K4me3 and assay for transposase-accessible chromatin using sequencing (ATAC-seq) measured in brain tissues 41 and contained two SNPs with significant allele-specific effects 42 on MAPK3 (Supplementary Note and Supplementary Figs. 36-39) . Strikingly, these peaks overlapped two recently identified human gained neurodevelopmental enhancers in independent fetal cortex tissues 43 ( Supplementary Fig. 36 ). This class of enhancers clusters with genes important for cortical development and neuronal differentiation and has been hypothesized to play a key role in human cortical evolution.
Functional interrogation of mapk3 in zebrafish. MAPK3 maps within the 16p11.2 600-kb copy number variant that has been associated with both schizophrenia and autism [44] [45] [46] [47] [48] . Previous studies have shown that dosage perturbation of another transcript in that region, KCTD13 can induce reciprocal head-size and neuronal proliferative defects, characteristics consistent with the anatomical pathology in patients 44 . Critically, pairwise dosage analyses have shown a genetic interaction of KCTD13 with MAPK3 (as well as a third locus, MVP) 44 , whereas independent transcriptional studies in human cells and mouse models have highlighted a functional 'cassette' composed of KCTD13, MVP, and MAPK3, a set of coregulated genes associated with the head-size phenotype 47 . Together with our TWAS observations, these data implicate a transcriptional relationship between these genes in the 16p11.2 region and suggest that MAPK3 (and its expression) might be a functional trigger. If so, suppression of MAPK3 should rescue the pathology induced by increased expression of KCTD13. To test this hypothesis, we performed an experimental assay in zebrafish embryos (Methods). In agreement with findings from prior studies, overexpression of human KCTD13 (associated with microcephaly in humans) induced both a decrease in head size and a concomitant decrease in the number of cycling cells in the brain (Fig. 6) . However, suppression of endogenous mapk3 in KCTD13-overexpressing embryos rescued both phenotypes reproducibly (Fig. 6 ).
Discussion
The landmark PGC schizophrenia GWAS paper has concluded that "if most risk variants are regulatory, available eQTL catalogues do not yet provide power, cellular specificity, or developmental diversity to provide clear mechanistic hypotheses for follow-up experiments" 1 . In this work, we integrated data from GWAS, expression, splicing, and chromatin activity to identify mechanistic hypotheses. We found 157 unique genes with transcriptome-wide-significant associations with schizophrenia, which were significantly supported by chromatin contact measured during brain development. Genes below the transcriptome-wide-significance threshold continued to be strongly associated with schizophrenia and exhibited enrichment for expression and splicing in the brain (though this result may also reflect expression-data quality). Associations for splicing events that were independent of total expression highlighted an important source of disease-relevant variation 27 with potential therapeutic implications 49, 50 . Notably, 42 of the 157 schizophrenia-associated genes were significantly associated with nearby chromatin phenotypes, thus implicating specific regulatory features for functional follow-up. We interrogated one TWAS association, MAPK3, in zebrafish embryos and observed a significant effect on neurodevelopmental phenotypes with consistent direction; thus, we prioritized this as a candidate for further follow-up.
We conclude with several limitations and future directions of this study. First, although TWAS is not confounded by reverse causality (disease → expression independent of SNP), instances of pleiotropy (in which a SNP or linked SNPs influence schizophrenia and expression independently) are statistically indistinguishable from truly causal susceptibility genes. As more molecular studies are performed, and the chance of incidental QTL-GWAS overlap increases, experimental causal inference is necessary to validate these findings. Second, the chromatin phenotypes analyzed here were measured in LCLs (because population-level chromatin data from other tissues are currently unavailable), thus preventing us from identifying brain-specific expression-chromatin associations. Third, the use of summary-based data necessitates linear predictors of expression, which may lead to misinterpretation of relationships between expression and disease/chromatin, if, for example, the weaker/secondary eQTLs/cQTLs have stronger effects on the trait because of context specificity. Finally, although we did not observe significant pathway/ontology enrichment for the identified susceptibility genes, we posit that these genes and chromatin features may serve as anchors for network-based analyses of genomewide coexpression and co-regulation; we view this direction as an intriguing prospect for future investigation.
Because tissue acquisition may pose the greatest hurdle for producing larger datasets, methods that do not depend on measurements from the same samples will remain critical. Beyond specific mechanistic findings for schizophrenia, this work outlines a systematic approach to identify functional mediators of complex disease. predictive accuracy and validation. Given a 1-by-M vector z of signed association statistics in the discovery study (for example, PGC) and an N-by-M matrix X of predicted expression for the corresponding M genes in the replication study, we constructed a GE-PRS S = Xz. The M genes were either all transcriptome-widesignificant genes (Supplementary Note) or all genes passing relaxed P-value thresholds. This risk score was then tested with ancestry against case/control status with the standard linear model y ~ S + P + e, where S is the risk score, and P is a matrix of PCs accounting for ancestry. Risk-score performance was measured as the linear R 2 from the above model minus the R 2 from the model y ~ P + e to account for ancestry and was converted to the liability scale assuming a prevalence of 1%.
URLs
For the TWAS using METSIM, YFS, and NTR expression reference panels, the cis-genetic component of expression was predicted in CMC samples. For the TWAS using the CMC expression panel, either the total expression was used ( Supplementary Fig. 13 ) or the cis-genetic component of expression was estimated directly with BSLMM (equivalent up to a scaling factor to estimate genetic values by dropping each individual in turn). We stress that the case/control label from the CMC data was never used to identify the TWAS associations, and that the GePRS from the CMC expression panel were thus evaluated against an independent CMC case/control phenotype. Ascertaining cases in the CMC expression panel may increase the frequency of causal variants and may consequently make the prediction more accurate than using a randomly ascertained expression panel; however, we observed little difference when performing the TWAS using an expression panel consisting of CMC controls only (Supplementary Table 4 ).
Individual-level chromatin TWAS.
We used cis SNP-expression effect sizes computed according to BSLMM scores in the four expression reference panels (including splicing events) to predict individual-level expression for the 45 CEU 18 and 76 YRI 6 individuals with measured chromatin phenotypes. We retained only post-QC SNPs that were typed in both studies and removed strand-ambiguous SNPs. We note that even though the YRI target samples are of different ancestry, this prediction does not require an LD reference panel and is therefore expected to suffer loss in only power (but not increased type I error), owing to the differences in LD. For each predicted gene, we identified all chromatin peaks within a given window of the TSS (primary results used ± 500 kb) and tested each mark for association with predicted expression by linear regression.
Top eSNP-cQTL overlap analysis. We compared the chromatin TWAS to a traditional approach of identifying SNPs that are significant both as cQTLs and eQTLs in real data. For each population and given distance to TSS, we performed this analysis in two stages. In stage 1, we used fastQTL 39 to identify the most significantly associated eSNP for each gene by permuting the expression and retesting the cis locus, and restricted analysis to those genes with eSNP P <0.01 (for consistency with the TWAS gene selection). In stage 2, each significant eSNP from stage 1 was then tested for association with all nearby chromatin peaks by standard linear regression, and those passing Bonferroni correction for all gene-peak pairs for each chromatin phenotype (for example, H3K27ac in CEU) were reported. This analysis was compared with the chromatin TWAS analysis in which each gene was tested against any peak within the given distance (by standard linear regression), and the number of significant results was reported after Bonferroni correction for the total number of gene-peak pairs tested in that phenotype. We separately considered an approach in which all significant eQTLs in a gene were evaluated for overlap (as in refs 6 and 18 ); however, this approach underperformed the permuted top eSNP-cQTL approach here (Supplementary Note).
Multiple-hypothesis correction for chromatin TWAS. The large number of correlated phenotypes analyzed (expression from five experiments and chromatin from nine experiments in two populations) allowed for several approaches to multiple-testing correction. For the chromatin TWAS, we corrected for the number of gene-peak pairs tested within a single expression reference and chromatin phenotype experiment (for example, the number of gene-peak pairs in evaluation of predicted CMC expression with the CEU H3K27ac chromatin phenotype). This procedure is directly comparable to the experiment-wide corrections applied in previous eQTL-cQTL analyses 6, 18 . The same correction was applied for the schizophrenia-chromatin TWAS overlap: for example, the 44 schizophrenia TWAS genes identified on the basis of CMC expression were within 500 kb of 1,528 total peaks in the CEU H3K27ac experiment, and 'overlap' was reported for any peak with a chromatin TWAS association P <0.05/1,528.
For comparison, we separately calculated the number of associations that were significant at 5% FDR across all molecular experiments. This process yielded approximately 3.5× more chromatin TWAS associations and 1.2× more schizophrenia and chromatin TWAS associations (Supplementary Table 2 ), thus demonstrating that the above experiment-wide Bonferroni correction strategy corresponded to a conservative study-wide FDR.
Estimating support for mediation by expression/chromatin. We sought to evaluate the evidence in support of two models of mediation: M CH , in which SNP → chromatin → expression → disease, and M EX , in which SNP → expression → chromatin → disease. Under the assumption of linear, additive variance across molecular phenotypes, this parameter can be estimated via the ratio of genetic covariance (cov g ) between chromatin-schizophrenia and expressionschizophrenia. Conceptually, the genetic effect of a given molecular phenotype on schizophrenia will be attenuated by environmental noise, which will manifest as lower cov g to schizophrenia for phenotypes further along the molecular cascade. The fraction of environmental variance on expression (env EX ) under each model of mediation can then computed from the following equation (derivation in Supplementary Note):
We inferred these quantities from both CEU and YRI, using cov g estimates from cross-trait LD-score regression 56 and computed significance by comparing against randomly sampled gene-peak pairs within 500 kb of the TSS. We separately considered a partial correlation approach using residuals of expression and chromatin in turn (Supplementary Note). We caution that the estimate of env in the above equation was computed from an average across all loci and may also be consistent with confounding from different levels of measurement error for ChIPseq and RNA-seq, a mixture of models M CH and M EX that favors model M CH , or mediation by other unobserved molecular phenotypes.
In vivo complementation in zebrafish embryos and whole-mount immunostaining. The human WT mRNA of KCTD13 (NM_178863) was cloned into the pCS2+ vector and transcribed in vitro with aSP6 Message Machine kit (Ambion), as previously described 44 . To suppress endogenous mapk3, we identified ENSDART00000103746.5 with 93% similarity and 88% identity to human MAPK3 (NM_002746) as the sole zebrafish ortholog, against which we designed a splice-blocking MO targeting exon 2 (mapk3sb: CTGTGAGTGTTTAAGGATACACATC). We injected 10 ng of mapk3 MO and 150 pg of WT KCTD13 RNA alone and in combination into WT zebrafish embryos at the one-to four-cell stage. For the evaluation of neuronal proliferation, antiphosphor histone 3 (PH3) (Ser10)-R (sc-8656-R, rabbit, Santa Cruz; 1:500) was used, and experiments were performed as previously described 57 . Proliferating neurons were quantified by counting all positive cells on a dorsal view of 3-dpf embryos, excluding the eyes from the scored area, by using the ITCN ImageJ plugin, which considers cells with 20-pixel width and 5-pixel minimum distance between them to be separate cells. Statistical significance for this assay was established with two-tailed Student's t test. For the head-size assay, injected larvae were grown to 4 dpf and imaged live on dorsal view. The area of the head, excluding the eyes, was traced from the measurements, and statistical significance was calculated with two-tailed Student's t test. Zebrafish embryos and adults were maintained and mated according to standard procedures, and all experiments were carried out with the approval of the Institutional Animal Care and Use Committee (IACUC).
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. The data and methods that support the findings of this study are available through the following links: TWAS results (http://www.gusevlab. org/projects/chromatinTWAS/) and TWAS methods (http://www.gusevlab.org/ projects/fusion/).
